{"version":"1.0","type":"link","title":"The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China.","author_name":"Ma L 외","author_url":"https://prs-insight.online/author/Ma%20L","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/107874","thumbnail_width":1200,"thumbnail_height":630}